Azithromycin nanocrystals for dermal prevention of tick bite infections

Azithromycin was optimized as nanocrystals with a drug content of 10.0 % (w/w) and a surfactant D- -tocopheryl polyethylenglycol 1000 succinate (TPGS) content of 1.0 % (w/w) using bead milling for 10 min. The photon correlation spectroscopy (PCS) diameter of the bulk population was 189 nm, laser dif...

Full description

Saved in:
Bibliographic Details
Published inPharmazie Vol. 74; no. 5; p. 277
Main Authors Jin, Nan, Pyo, Sung Min, Keck, C M, Müller, R H
Format Journal Article
LanguageEnglish
Published Germany 01.05.2019
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Azithromycin was optimized as nanocrystals with a drug content of 10.0 % (w/w) and a surfactant D- -tocopheryl polyethylenglycol 1000 succinate (TPGS) content of 1.0 % (w/w) using bead milling for 10 min. The photon correlation spectroscopy (PCS) diameter of the bulk population was 189 nm, laser diffraction (LD) diameter 90 % was 370 nm. Spherical morphology of the optimal nanocrystals was observed by transmission electron microscope (TEM). They were stable over 1 year of storage at 4 °C with the particle size within the nanometer range which was confirmed by PCS, LD and light microscope. An acceptable physical stability of 2 years was also obtained when stored at 4 °C. No microbial attack to the nanocrystals was observed before 3 years storage at 4 °C. The saturation solubility of the nanocrystals was up to triple compared to the raw drug powder (RDP) in water. When incorporated into the gel base, highest penetration efficacy was achieved by the optimal nanocrystals compared to 1) the clinically effective ethanol-solution-gel, 2) the gel with propylene glycol and 3) the gel with RDP in the porcine ear penetration study. Even though propylene glycol improved saturation solubility of nanocrystals, it could not bring benefit to nanocrystals in the penetration study. Based on these optimized azithromycin nanocrystals, topical administration for enhanced dermal bioavailability of azithromycin seems to be feasible.
ISSN:0031-7144
DOI:10.1691/ph.2019.8169